Protect Patients from Costly Care Act | ChamberLight
Bills · HR 5094
IN COMMITTEE· 119TH CONGRESS
House BillHR 5094Health
Protect Patients from Costly Care Act
INTRO SEP 2· LAST ACTION SEP 2
READING
2MIN
COSPONSORS
9
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8
Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-written
This bill matters because it directly addresses the affordability of healthcare for vulnerable populations. For Medicaid recipients, it means potentially paying less for essential medical care, which can be crucial for families struggling financially. If the bill doesn't pass, Medicaid cost-sharing could remain higher, potentially creating financial barriers to care for millions of low-income Americans.
For Medicare patients with rare diseases, the bill could lead to lower prescription drug costs for life-saving or life-altering orphan drugs. High drug prices are a significant concern for many Americans, and if this bill becomes law, it could expand the government's ability to get better deals on these specialized medicines. If it doesn't pass, the current rules regarding orphan drug negotiation would remain, potentially keeping prices higher for patients.
KEY PROVISIONS
3AI-extracted
PROVISION 01
This bill undoes a previous law's changes that increased how much Medicaid patients have to pay for their healthcare.
This provision aims to make healthcare more affordable for low-income individuals and families by reducing their out-of-pocket costs.
PROVISION 02
This bill cancels any funding that was set aside for implementing the previous law's increased Medicaid cost-sharing.
It financially reinforces the repeal of the increased cost-sharing by removing the dedicated funds for those changes.
PROVISION 03
This bill reverses a previous law's changes to the rules about which orphan drugs are exempt from Medicare's price negotiation program.
It could allow Medicare to negotiate prices for more drugs for rare diseases, potentially lowering costs for patients.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters because it directly addresses the affordability of healthcare for vulnerable populations. For Medicaid recipients, it means potentially paying less for essential medical care, which can be crucial for families struggling financially. If the bill doesn't pass, Medicaid cost-sharing could remain higher, potentially creating financial barriers to care for millions of low-income Americans.
For Medicare patients with rare diseases, the bill could lead to lower prescription drug costs for life-saving or life-altering orphan drugs. High drug prices are a significant concern for many Americans, and if this bill becomes law, it could expand the government's ability to get better deals on these specialized medicines. If it doesn't pass, the current rules regarding orphan drug negotiation would remain, potentially keeping prices higher for patients.
KEY PROVISIONS
AI-extracted
high
This bill undoes a previous law's changes that increased how much Medicaid patients have to pay for their healthcare.
This provision aims to make healthcare more affordable for low-income individuals and families by reducing their out-of-pocket costs.
med
This bill cancels any funding that was set aside for implementing the previous law's increased Medicaid cost-sharing.
It financially reinforces the repeal of the increased cost-sharing by removing the dedicated funds for those changes.
high
This bill reverses a previous law's changes to the rules about which orphan drugs are exempt from Medicare's price negotiation program.
It could allow Medicare to negotiate prices for more drugs for rare diseases, potentially lowering costs for patients.
GLOSSARY
AI-written
Medicaid Cost-Sharing
The portion of healthcare costs, like copayments or deductibles, that people covered by Medicaid might have to pay out-of-pocket for services.
Orphan Drugs
Medications developed to treat rare diseases or conditions that affect only a small number of people.
Medicare Drug Price Negotiation Program
A government program under Medicare designed to negotiate lower prices for certain prescription drugs directly with pharmaceutical manufacturers.
Repeal
To formally cancel or revoke a law or a specific section of a law.
Rescind
To cancel or revoke an appropriation or authorization, meaning the money previously set aside for a purpose is no longer available.
Public Law 119-21
A specific previous law whose provisions related to Medicaid cost-sharing and orphan drug exclusions are being targeted for reversal by this bill.
Title XIX of the Social Security Act
The section of federal law that established the Medicaid program.
ACTION TIMELINE
2 EVENTS
SEP 2, 25
Introduced in House
INTROREFERRAL
SEP 2, 25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A section of federal law that contains general provisions relating to the Social Security Act, under which the Medicare Drug Price Negotiation Program provisions (including those related to orphan drugs) would fall.
